ORIGINAL
ARTICLE
Randomized Trial of Aromatase Inhibitors, Growth
Hormone, or Combination in Pubertal Boys with
Idiopathic, Short Stature
Nelly Mauras, Judith L. Ross, Priscila Gagliardi, Y. Miles Yu, Jobayer Hossain,
Joseph Permuy, Ligeia Damaso, Debbie Merinbaum, Ravinder J. Singh,
Ximena Gaete, and Veronica Mericq
Nemours Children’s Health System, Division of Endocrinology (N.M., P.G., J.P., L.D.), Jacksonville, Florida
32207; (J.L.R.), Philadelphia, Pennsylvania 19107; and (Y.M.Y.), Orlando, Florida 32827; Nemours
Children’s Health System, Division of Biostatistics (J.H.), Wilmington, Delaware 19803; and Nemours
Children’s Health System, Department of Radiology (D.M.), Jacksonville, Florida 32207; Mayo Clinic
(R.J.S.), Department of Biochemistry, Rochester, Minnesota 55905; and University of Chile (X.G., V.M.),
Division of Endocrinology, 1058 Santiago, Chile
Context: Growth of short children in puberty is limited by the effect of estrogen on epiphyseal fusion.
Objectives: To compare: 1) the efficacy and safety of aromatase inhibitors (AIs) vs GH vs AI/GH on
increasing adult height potential in pubertal boys with severe idiopathic short stature (ISS); and 2)
differences in body composition among groups.
Design: Randomized three-arm open-label comparator.
Setting: Outpatient clinical research.
Patients: Seventy-six pubertal boys [mean (SE) age, 14.1 (0.1) years] with ISS [height SD score (SDS),
⫺2.3 (0.0)].
Intervention: Daily AIs (anastrozole or letrozole), GH, or AI/GH for 24 –36 months.
Outcomes: Anthropometry, bone ages, dual x-ray absorptiometry, spine x-rays, hormones, safety labs.
Results: Height gain [mean (SE)] at 24 months was: AI, ⫹14.0 (0.8) cm; GH, ⫹17.1 (0.9) cm; AI/GH,
⫹18.9 (0.8) cm (P ⬍ .0006, analysis of covariance). Height SDS was: AI, ⫺1.73 (0.12); GH, ⫺1.43 (0.14);
AI/GH, ⫺1.25 (0.12) (P ⬍ .0012). Those treated through 36 months grew more. Regardless of
treatment duration, height SDS at near-final height [n ⫽ 71; age, 17.4 (0.2) years; bone age, 15.3
(0.1) years; height achieved, ⬃97.6%] was: AI, ⫺1.4 (0.1); GH, ⫺1.4 (0.2); AI/GH, ⫺1.0 (0.1) (P ⫽ .06).
Absolute height change was: AI, ⫹18.2 (1.6) cm; GH, ⫹20.6 (1.5) cm; AI/GH, ⫹22.5 (1.4) cm (P ⫽ .01)
(expected height gain at ⫺2.0 height SDS, ⫹13.0 cm). AI/GH had higher fat free mass accrual.
Measures of bone health, safety labs, and adverse events were similar in all groups. Letrozole
caused higher T and lower estradiol than anastrozole.
Conclusions: Combination therapy with AI/GH increases height potential in pubertal boys with ISS
more than GH and AI alone treated for 24 –36 months with a strong safety profile. (J Clin Endocrinol
Metab 101: 4984 – 4993, 2016)
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA
Copyright © 2016 by the Endocrine Society
Received August 2, 2016. Accepted October 3, 2016.
First Published Online October 6, 2016
4984
press.endocrine.org/journal/jcem
Abbreviations: AE, adverse event; AI, aromatase inhibitor; ANCOVA, analysis of covariance;
BMD, bone mineral density; BMI, body mass index; CV, coefficient of variation; DXA, dual
x-ray absorptiometry; FFM, fat free mass; GnRHa, GnRH analog; ISS, idiopathic short
stature; SAE, serious AE; SCFE, slipped capital femoral epiphyses; SDS, SD score.
J Clin Endocrinol Metab, December 2016, 101(12):4984 – 4993
doi: 10.1210/jc.2016-2891
The Endocrine Society. Downloaded from press.endocrine.org by [Elham Faghihimani] on 26 December 2016. at 04:12 For personal use only. No other uses without permission. . All rights reserved.
doi: 10.1210/jc.2016-2891
I
ncreasing height potential in growth-retarded children
during puberty is often complicated by the inexorable
tempo of epiphyseal fusion caused by pubertal sex steroids, greatly limiting the time available for growth. Highdose GH (1) or GnRH analogs (GnRHa) combined with
GH have been used with positive, albeit variable, results
(2– 6). Although GnRHa treatment is effective in delaying
epiphyseal fusion, it renders youngsters hypogonadal at a
critical time of development. Studies of males with mutations in the estrogen receptor gene (7) or the aromatase
enzyme gene (8, 9), and animal data (10) have shown that
estrogen is the principal regulator of epiphyseal fusion in
both genders. Estrogen decreases progenitor cells in resting state chondrocytes and increases structural senescence
(11), mostly through an estrogen receptor ␣-mediated
mechanism. Hence, more selective suppression of estrogen
production or action can promote linear growth while
allowing continued sexual maturation in males.
Aromatase inhibitors (AIs) block the conversion of androgens to estrogens with significant selectivity and potency and are approved by the Food and Drug Administration (FDA) in postmenopausal women with breast
cancer. AIs in young males have similar pharmacokinetics
as those reported in women (12, 13). We observed that
GnRHa treatment had significant catabolic effects in
males, diminishing rates of whole-body protein synthesis,
increasing urinary calcium excretion, and increasing adiposity (14, 15), effects not seen with aromatase blockade
at least for the time window of the studies (16).
Studies in boys with constitutional growth delay (17),
idiopathic short stature (ISS) (18), and GH deficiency (19)
treated with AIs alone (18) or combined with T (17) or
with GH (19) have shown promising results, with treatment enhancing height potential by delaying epiphyseal
fusion while promoting linear growth. In adolescent boys
with GH deficiency treated with GH, addition of anastrozole increased height potential by ⫹4.5 cm after 24
months and by ⫹6.7 cm after 36 months of combined
treatment, vs ⫹1.0-cm gain with placebo and GH at the
same time points (19).
We designed these studies to better assess the impact of
AIs (both anastrozole and letrozole), vs GH, vs combination AI/GH on increasing adult height potential in adolescent boys with ISS. We also aimed to assess bone density
and morphology and lean body mass accrual with treatments. As secondary aims, we investigated the degree of
aromatase suppression using letrozole vs anastrozole using highly sensitive assays.
Subjects and Methods
Study subjects
Studies were conducted at the Pediatric Endocrine Clinics at
Nemours Children’s Health System in Jacksonville, Florida; and
press.endocrine.org/journal/jcem
4985
Philadelphia, Pennsylvania; and at the University of Chile after
institutional review board approvals. Informed written consent
was obtained from participants, parents, and children as appropriate. Inclusion criteria included boys ages ⱖ12 and ⬍18
years with ISS and residual height potential (bone age ⱕ14 1⁄2
years) who were in puberty. ISS was defined as a height SD
score (SDS) ⱕ⫺2.0 and no other hormonal, skeletal, or systemic pathology identified. Subjects had GH stimulation tests
with peak GH responses of ⱖ5 ng/mL and/or normal IGF-1
and IGF binding protein-3 before study entry. All were naive
to treatment and had normal birth weight. Studies were registered at clinicaltrials.gov (NCT01248416).
Study design
At baseline all subjects had a physical examination and pubertal staging using the standards of Tanner (20). Anthropometric measures were obtained using Harpenden stadiometers and
digital scales. A left hand and wrist x-ray was obtained for bone
age determination, and dual x-ray absorptiometry (DXA) of the
lumbar spine (anteroposterior and lateral) and whole body was
performed. Blood and urine samples were collected in the early
morning. Subjects were then randomized to treatment with an AI
(anastrozole or letrozole— balanced 1:1), somatropin (GH), or
combination treatment (AI/GH) for the next 24 months. The
protocol was amended to continue treatment for another 12
months (36 months total) if the subject had residual height potential and he and his family wished to continue on an active
drug. Protocol milestones were at 0, 3, 6, 9, 12, 18, and 24
months, and if treatment continued, at 30 and 36 months also.
When possible, subjects were followed for at least another 12
months after discontinuation of treatment, and several were followed beyond this timeline if they continued growing. All adverse events (AEs) and serious AEs (SAEs) were carefully recorded and were reported quarterly to the study’s data safety
management board. An abbreviated bone questionnaire was
used to assess bone discomfort or pain throughout the study (21).
Study drugs
An investigational new drug number was assigned by the
FDA. Drug supply agreements were provided in kind for anastrozole (Arimidex; AstraZeneca), letrozole (Femara; Novartis),
and GH (Nutropin AQ, Genentech; and Genotropin, Pfizer).
Depending on randomization, daily doses were: anastrozole, 1
mg orally; letrozole, 2.5 mg orally; and GH, approximately 42
g/kg/d sc.
Assays
T and estradiol concentrations were measured by tandem
liquid chromatography mass spectrometry (Agilent Technologies, Inc) at Mayo Clinic laboratories. Plasma 17 -estradiol was
extracted with methylene chloride and derivatized with dansyl
chloride, followed by high-pressure liquid chromatography and
tandem liquid chromatography mass spectrometry. Intra-assay
coefficients of variation (CVs) were 6.0/1.6% at 0.74 and 35
pg/mL, respectively; interassay CVs were 6.9/5.1% at 0.77 and
32 pg/mL; lower assay sensitivity was 0.3 pg/mL. T intra-assay
CVs were 2.3– 0.9% and interassay CVs were 3.5%. IGF-1 was
measured at the Nemours Biochemical Analysis Laboratory using ELISA (R&D Systems), with a 4.0% intra-assay CV. General
chemistries and plasma lipids were measured by automated
chemistry analyzers.
The Endocrine Society. Downloaded from press.endocrine.org by [Elham Faghihimani] on 26 December 2016. at 04:12 For personal use only. No other uses without permission. . All rights reserved.
4986
Mauras et al
Aromatase Inhibitors (AI), GH & AI/GH in ISS Boys
X-rays and DXA
Left hand and wrist x-rays for bone age were centrally read by
a single reader at Fels Institute (Ohio) (22) and predicted adult
height calculated using Bayley Pinneau tables (23). DXA of the
lumbar spine (anteroposterior, lateral) measured L1–L4, and
whole-body DXA was performed using either a Hologic (Discovery or Horizon) or Lunar densitometer; the same software/
instrument was used per subject throughout the trial. If not available through DXA, a lateral thoracic plain x-ray was obtained to
assess bone morphology. A single radiologist (D.M.) who was
blinded to treatment reviewed and scored all spine films for vertebral changes including: disc space narrowing, wedging, compression, and irregularity. Z-scores were corrected for height
(24).
Statistical analysis
Descriptive statistics, mean (⫾ SE) were used as appropriate.
These studies were not powered to sort out efficacy by type of AI
on anthropometric and body composition metrics. Hence, data
were grouped by randomization arm regardless of AI type, either
anastrozole or letrozole for analysis of covariance (ANCOVA)
or repeated measures ANOVA, to compare changes between
treatment groups at 24 and 36 months and near-final height
within and between groups. When comparing within and between treatment group changes in mean responses over time
involving more than two time points (eg, DXA bone mineral
density [BMD] Z-scores at 0, 12, and 24 months), we performed
mixed-effects repeated-measures ANOVA. Two-factor ANCOVA using type and length of treatment was used to compare
means changes in near-final height. Models were adjusted for
baseline values as appropriate, and assumptions were checked.
Nonparametric Kruskal-Wallis tests were used for comparisons
when appropriate. Whenever possible, subjects were measured
until growth velocity was ⬍2 cm/y and/or bone age was ⱖ16
years. If the subject was not located or was unable to be seen, the
last measurement was used as the last height. Significance was
established at P ⬍ .05. The only subanalysis performed by type
of AI was the degree of suppression of aromatase based on
changes in T and estradiol concentrations. The statistical software SAS version 9.3 (SAS Institute. Inc) was used for analysis.
Results
Seventy-six adolescent boys were recruited in three treatment groups (AI, GH, and AI/GH) and were well-matched
Table 1.
J Clin Endocrinol Metab, December 2016, 101(12):4984 – 4993
for age, height, BMI, and midparental height (Table 1). Of
those, 72 completed all procedures at 12 months, 68 at 18
months, and 65 at 24 months. If subjects had residual
height potential at 24 months (n ⫽ 54), they could choose
to continue (n ⫽ 19) or discontinue medication (n ⫽ 35);
all 54 had procedures completed by 36 months. Three
subjects changed treatment at 24 months; two on AI-only
added GH, one on AI/GH discontinued AI, and their data
were excluded from the post 24-month analysis. Regardless of treatment, 71 subjects have been followed to nearfinal height (Supplemental Figure 1).
Growth parameters and bone age
All patients grew during the initial 24 months of treatment; hence, all within-group changes are highly significant (between-group comparisons are shown in parentheses): mean change (SE)—AI, ⫹14.0 (0.8) cm; GH, ⫹17.1
(0.9) cm; AI/GH, ⫹18.9 (0.8) cm (P ⬍ .0006 between
groups) (P value represents the probability of difference in
mean changes between groups for all parameters. ANCOVA was used and model adjusted for baseline height.).
The expected height gain in boys with height SDS of ⫺2.0
is ⫹10.1 cm in the same age period (25). At 36 months,
those who continued treatments grew more (between 24
and 36 months) than those who discontinued: continued—AI, ⫹4.9 (1.0) cm; GH, ⫹6.8 (0.4) cm; AI/GH, ⫹7.8
(0.5) cm (P ⫽ .032) (P value represents the probability of
difference in mean changes between groups for all parameters. ANCOVA was used and model adjusted for baseline
height.); discontinued—AI, ⫹4.1 (1.1) cm; GH, ⫹2.1
(0.6) cm; AI/GH, 3.0 (0.5) cm (P ⫽ .103) (P value represents the probability of difference in mean changes between groups for all parameters. ANCOVA was used and
model adjusted for baseline height.) (P ⫽ ⬍ .001) [P value
of overall difference in mean changes (from 24 mo to 36
mo) between continued and discontinued group]. Mean
absolute height SDS in all three groups was comparable at
baseline (⫺2.2 to ⫺2.4 SDS) and improved at 24 months:
AI, ⫺1.73 (0.12) SDS; GH, ⫺1.43 (0.14) SDS; AI/GH,
⫺1.25 (0.12) SDS (P ⬍ .0012) (P value represents the
Clinical Characteristics of Study Subjects at Baseline
n
Age, y
Height, cm
Height SDS
BMI, kg/m2
Bone age, y
MPH, cm
IGF-1, ng/mL
T, ng/dL
All
AI
GH
AI/GH
76
14.1 ⫾ 0.1
144.8 ⫾ 0.7
⫺2.3 ⫾ 0.0
18.7 ⫾ 0.3
12.8 ⫾ 0.1
171.1 ⫾ 0.6
161 ⫾ 10
223 ⫾ 22
25
14.2 ⫾ 0.2
145.7 ⫾ 1.1
⫺2.2 ⫾ 0.1
18.4 ⫾ 0.4
12.8 ⫾ 0.3
171.8 ⫾ 0.8
146 ⫾ 12
205 ⫾ 37
25
14.1 ⫾ 0.2
144.2 ⫾ 1.4
⫺2.4 ⫾ 0.1
18.4 ⫾ 0.6
12.9 ⫾ 0.3
170.1 ⫾ 1.3
154 ⫾ 15
244 ⫾ 39
26
14.0 ⫾ 0.2
144.5 ⫾ 1.3
⫺2.3 ⫾ 0.1
19.2 ⫾ 0.5
12.7 ⫾ 0.2
171.6 ⫾ 0.9
181 ⫾ 23
222 ⫾ 37
Abbreviation: MPH, midparental height. Data are expressed as mean ⫾ SE.
The Endocrine Society. Downloaded from press.endocrine.org by [Elham Faghihimani] on 26 December 2016. at 04:12 For personal use only. No other uses without permission. . All rights reserved.
doi: 10.1210/jc.2016-2891
press.endocrine.org/journal/jcem
4987
gardless of whether or not they continued on treatment past 24 months,
the last measured mean absolute
height was as follows: AI, 164.1 (1.6)
cm; GH, 164.8 (1.6) cm; AI/GH,
166.9 (1.5) cm (P ⫽ .19 among
groups); whereas adult height at
⫺2.0 SDS is 160.9 cm (25) (Figure
2A). Height SDS at near-final height
was: AI, ⫺1.4 (0.1); GH, ⫺1.4 (0.2);
AI/GH, ⫺1.0 (0.1) (P ⫽ .06) (P value
represents the probability of difference in mean changes between
groups for all parameters. ANCOVA was used and model adjusted
for baseline height.). The absolute
change in height from baseline at
near-final height was highly significant within groups (P ⬍ .0001 each):
AI, ⫹18.2 (1.6) cm; GH, ⫹20.6 (1.5)
cm; AI/GH, ⫹22.5 (1.4) cm (P ⫽ .01
between all groups (P value represents the probability of difference in
mean changes between all groups using 2 factor ANOVA model including treatment type and duration),
P ⫽ .002 between AI and AI/GH
Figure 1. Changes in mean (SE) height SDS (top panel) and bone age (bottom panel) over
groups); the expected height gain in
24 months in the groups treated with AIs, GH, and AI/GH. *, P ⬍ .0012 (top panel); and
boys with height SDS of ⫺2.0 is
**, P ⫽ .002 (bottom panel) represent the probability of difference in mean changes between
groups for all parameters (ANCOVA). n ⫽ 76 (baseline), 72 (12 months), and 65 (24 months).
⫹13.0 cm (25) (Figure 2B); our subjects were even shorter (height SDS,
⫺2.2 to ⫺2.4). When data of subprobability of difference in mean changes between groups
jects who continued their medications through 36 months
for all parameters. ANCOVA was used and model adwere separated from data of those who discontinued at
justed for baseline height.) (Figure 1A). The change in
24 months, the overall net gain in height at near-final
bone age in 24 months from baseline was: AI, ⫹2.1 (0.3)
height from baseline was greater in those who continued
years; GH, ⫹2.5 (0.1) years; AI/GH, ⫹1.9 (0.2) years (P ⫽
(P ⬍ .0001): continued treatment—AI, ⫹23.8 (2.3) cm;
.002) (P value represents the probability of difference
in mean changes between groups for all parameters. GH, ⫹26.7 (2.0) cm; AI/GH, ⫹30.7 (1.1) cm (P ⫽ .06
ANCOVA was used and model adjusted for baseline between treatment groups) (P value represents the probheight.), larger change for the GH group (Figure 1B). ability of difference in mean changes between groups for
Height SDS adjusted for bone age at 24 months was: AI, all parameters. ANCOVA was used and model adjusted
⫺1.06 (0.14); GH, ⫺1.11 (0.20); AI/GH, ⫺0.41 (0.13) for baseline height.); discontinued treatment—AI,
(P ⫽ .0002) (P value represents the probability of differ- ⫹14.7 (1.5) cm; GH, ⫹ 17.8 (1.6) cm; AI/GH, 19.9 (1.4)
ence in mean changes between groups for all parameters. cm (P ⫽ .12 between groups) (P value represents the
ANCOVA was used and model adjusted for baseline probability of difference in mean changes between
groups for all parameters. ANCOVA was used and
height.).
Except for three subjects who switched treatment arms model adjusted for baseline height.).
Mean relative differences between estimated target
after 24 months and two lost to follow-up, all available
subjects (n ⫽ 71) have been followed as long as possible to (midparental) height and near-final height were: AI,
near-final height, with mean age of 17.4 (0.2) years and ⫺7.8 ⫾ 1.6 cm (10% of subjects were taller than target
bone age of 15.3 (0.1) years, which corresponds to 97.6% height); GH, ⫺5.3 ⫾ 1.3 cm (24% of subjects were taller);
of the height achieved. Using intent-to-treat analysis, re- AI/GH, ⫺4.5 ⫾ 1.4 cm (32% of subjects were taller) (P ⫽
The Endocrine Society. Downloaded from press.endocrine.org by [Elham Faghihimani] on 26 December 2016. at 04:12 For personal use only. No other uses without permission. . All rights reserved.
4988
Mauras et al
Aromatase Inhibitors (AI), GH & AI/GH in ISS Boys
J Clin Endocrinol Metab, December 2016, 101(12):4984 – 4993
at baseline and decreased in all
groups on treatment, but still within
the normal range. BMD Z-scores
were mildly low at the whole-body
level (reflective of mostly cortical
bone), diminishing in all groups, particularly the AI group, but still remaining within the normal range
(Table 2). Lateral thoracic spine xrays showed an array of vertebral
findings including disc space narrowing, wedging, compression,
and irregularities, many present at
baseline and comparable in all
three arms. Bone-specific alkaline
phosphatase, a marker of bone formation, was similar in all three
groups throughout 24 months of
treatment (Supplemental Table 1).
Body composition
There were differential responses in
body composition as boys progressed
through puberty, depending on treatment arm. Those on AI or GH accrued
fat free mass (FFM) similarly over 24
Figure 2. Top panel shows mean (SE) differences in near-final height (cm) (n ⫽ 71) in the AI,
months (DXA), whereas those on
GH, and AI/GH groups regardless of length of treatment (n ⫽ 21, 25, and 25, respectively)
combined AI/GH accrued more. FFM
(P ⬍ .001 within groups; *, P ⫽ .19 among groups). Bottom panel shows net gain in height (cm)
in the same three groups (*, P ⫽ .01 among groups; **, P ⫽ .002 between AI and AI/GH
values at 0, 12, and 24 months, respecgroups). Average height and net gain in height of young men of similar ages with height SDS
tively, were: AI, 30.9 (1.1), 38.6 (1.2),
⫺2.0 are shown for comparison on the far right bars (CDC data).
and 42.2 (1.6) kg (P ⱕ .0001); GH,
30.2 (1.0), 37.9 (1.4), and 42.0 (1.3)
.27 among groups). Those who continued treatment
kg
(P
ⱕ
.0001);
AI/GH,
31.3 (0.8), 42.3 (0.9), and 46.5 (1.2)
had lesser differences between near-final and target
kg
(P
ⱕ
.0001)
(P
⫽
.015
among groups). Percentage fat mass
height.
was lower in subjects on GH and AI/GH compared to AI
during treatment; values at 0, 12, and 24 months, respecBone assessments (Table 2)
Lumbar and whole-body BMD Z-scores were low in tively, were: AI, 18.4 (1.6); 18.7 (1.4); and 20.1 (1.0) (P ⫽
the entire cohort throughout the study. However, when .50); GH, 20.4 (1.6), 15.9 (1.5), and 16.3 (1.3) (P ⫽ .0012);
BMD Z-scores were adjusted for height (24), lumbar spine AI/GH, 20.4 (1.8), 14.2 (1.5), and 16.7 (1.1) (P ⬍ .0001)
scores (reflective mostly of trabecular bone) were normal (P ⫽ .003 among groups) (Figure 3).
Table 2.
Bone Assessments
Vertebral Findings
Disc Space Narrowing
DXA BMD Z Score Corrected
Wedging
Compression
Irregularity
Lumbara
Whole Bodyb
Months
AI
GH
AI/
GH
AI
GH
AI/
GH
AI
GH
AI/
GH
AI
GH
AI/
GH
AI
GH
AI/GH
AI
GH
AI/GH
0
12
24
2
5
3
3
3
2
4
6
6
2
3
2
0
0
0
1
0
0
0
0
0
0
0
0
4
0
0
1
1
1
1
0
0
0
0
1
0.372 ⫾ .187
0.043 ⫾ .181
⫺0.328 ⫾ .227
0.488 ⫾ .320
0.243 ⫾ .353
0.243 ⫾ .328
0.569 ⫾ .309
0.216 ⫾ .312
0.067 ⫾ .306
⫺0.328 ⫾ .232
⫺0.583 ⫾ .195
⫺1.061 ⫾ .313
⫺0.464 ⫾ .312
⫺0.700 ⫾ .309
⫺0.586 ⫾ .244
⫺0.062 ⫾ .252
⫺0.448 ⫾ .281
⫺0.605 ⫾ .257
a
P value of mean difference among groups for lumbar spine: 0 months, .99; 12 months, .52; 24 months, .03. Within-group changes over time:
AI, ⬍ .001; GH, .04; AI/GH, .001. Baseline, n ⫽ 76; 12 months, n ⫽ 72; 24 months, n ⫽ 62.
b
P value of mean difference among groups: 0 months, .93; 12 months, .46; 24 months, .906. Within-group changes over time: AI, .003; GH, .06;
AI/GH, ⬍.001.
The Endocrine Society. Downloaded from press.endocrine.org by [Elham Faghihimani] on 26 December 2016. at 04:12 For personal use only. No other uses without permission. . All rights reserved.
doi: 10.1210/jc.2016-2891
press.endocrine.org/journal/jcem
4989
Aromatase blockade caused a significant and comparable increase in
T concentrations with AI alone or
AI/GH, compared to GH alone, although still within normal range. At
0, 12, and 24 months, respectively, T
concentrations were: AI, 205 [to
convert to T (ng/dl) to nmol/L multiply by 0.0347] (37), 880 (80), and
737 (79) ng/dL (P ⱕ .0001 within
group); GH, 244 (39), 335 (43), and
372 (33) ng/dL (P ⫽ .007); and AI/
GH, 222 (37), 726 (60), and 668 (37)
ng/dL (P ⱕ .0001) (P ⬍ .0001 between groups). Estradiol concentrations at 0, 12, and 24 months were:
AI, 6.4 [estradiol (pg/ml) to pmol/L
multiply by 3.67] (1.0), 4.0 (0.9),
and 6.0 (2.5) pg/mL (P ⫽ .009); GH,
7.4 (1.1), 11.6 (1.7), and 13.6 (1.2)
pg/mL (P ⬍ .001); and AI/GH, 6.0
(0.9), 3.0 (0.6), and 5.1 (0.8) pg/mL
(P ⫽ .003) (P ⬍ .001 between
groups) (Figure 4).
We characterized the degree of
aromatase blockade by the type of
inhibitor used, based on changes on
sex steroid concentrations. Data on
those taking AI alone or AI/GH combined were grouped by type, either
Figure 3. Changes in FFM (top panel) and percentage fat mass (%FM) (bottom panel) over 24
anastrozole or letrozole. There were
months in the AI, GH, and AI/GH groups by DXA [mean (SE)]. FFM, P ⬍ .001 within each group;
significant differences in the levels of
*, P ⫽ .015 among groups; %FM, P ⫽ .50. AI, 0.0012; GH, ⬍ .0001; AI/GH, **, P ⫽ .003
T by AI at 0, 12, and 24 months, reamong groups. n ⫽ 76 (baseline), 72 (12 months), 63 (24 months).
spectively: anastrozole, 140 (37),
550 (64), and 509 (74) ng/dL; letroIGF-1 concentrations
zole, 256 (56), 1068 (87), 920 (97) ng/dL (P ⫽ .0002; P
IGF-1 concentrations remained constant during 24 value of differences between anastrozole/letrozole over
months of treatment in the AI group and increased in the time). There was a reciprocal greater decrease in estradiol
GH and AI/GH groups; values at 0, 12, and 24 months, after letrozole compared to anastrozole at 0, 12, and 24
respectively, were: AI, 146 (12), 144 (13), and 158 (14) months: anastrozole, 5 (1), 6 (2), and 8 (1) pg/mL; letrong/mL (P ⫽ .70); GH, 154 (15), 303 (22), and 280 (16) zole, 8 (1), 3 (1), and 4 (1) pg/mL (P ⫽ .0003) (P value of
ng/mL (P ⬍ .001); and AI/GH, 181 (23), 338 (21), and 303 differences between anastrozole/letrozole over time) (Sup(27) ng/mL (P ⬍ .001) (P ⬍ .0001 among groups) (Figure 4). plemental Figure 2).
Puberty progression and sex steroids
By design, study subjects were recruited in puberty,
with the average genital Tanner stage of 2–3 at study entry,
3– 4 by 12 months, and 4 –5 by 24 months in all three
groups. Testicular volumes were symmetrical and remained so throughout the study: AI, 10, 20, and 25 mL;
GH, 10, 15, and 20 mL; and AI/GH, 10, 20, and 25 mL at
0, 12, and 24 months, respectively.
Chemistries
Liver function tests and plasma lipids were measured
throughout the initial 24 months with no significant
changes over time (Supplemental Table 1).
Safety
All documented AEs are included in Supplemental
Table 2. In 36 months, there were 382 AEs in the entire
The Endocrine Society. Downloaded from press.endocrine.org by [Elham Faghihimani] on 26 December 2016. at 04:12 For personal use only. No other uses without permission. . All rights reserved.
4990
Mauras et al
Aromatase Inhibitors (AI), GH & AI/GH in ISS Boys
J Clin Endocrinol Metab, December 2016, 101(12):4984 – 4993
cussion after falling from a tree, testicular torsion with bell clapper congenital deformity, and vertebra
compression fracture after flipping
on a four-wheeler), two on GH
(pneumonia, and self-cutting episode), and three on AI/GH (upper
tibial fracture during soccer trauma,
vascular headaches present before
study, and slipped capital femoral
epiphyses [SCFE]). SCFE was
thought to be related to the study
drug (GH) and to the subject’s increased BMI (90th percentile).
Discussion
Management of significant short
stature in adolescence is challenging,
particularly in those naive to treatment, because the time window for
growth is limited. Differences between chronological age and bone
age are also eliminated as puberty
progresses. In this three-arm comparator study using AIs, GH, and
combination AI/GH, AIs performed
well, increasing linear growth when
used for 2–3 years, particularly when
combined with GH. For the first 24
months, patients showed a significant net gain in height from baseline
on AI/GH (⫹18.9 [0.8] cm) ⬎ GH
alone (⫹17.1 [0.9] cm) ⬎ AI alone
(⫹14.0 [0.8] cm). This translated
into a taller height SDS at 24 months
for AI/GH (⫺1.25 [0.12]) ⬎ GH
(⫺1.43 [0.14]) ⬎ AI (⫺1.73 [0.12])
SDS. Height SDS corrected for bone
age was even taller because the AI
groups had slower bone age progression. This growth compares favorably with an expected average net
gain in height of ⫹10.1 cm in boys
Figure 4. Changes in mean (SE) concentrations of T (top panel), estradiol (middle panel), and
the same age with an SDS of ⫺2.0
IGF-1 (bottom panel) in the AI, GH, and AI/GH groups (*, P ⬍ .0001 among groups for T and
cm; our subjects’ height SDS was
IGF-1; **, P ⬍ .001 for estradiol). n ⫽ 76 (baseline), 72 (12 months), 65 (24 months).
even shorter at ⫺2.2 to ⫺2.4. These
results are remarkable, considering
cohort, 118 in AI group, 114 GH group, and 150 AI/GH. that boys were older (average age, 14.1 years) at study
The most common AEs were musculoskeletal, mostly re- entry and quite short (height SDS, ⫺2.3) despite being well
lated to physical activity and sports injuries. There were in the midst of puberty (initial T, 223 ng/dL). Our data are
eight SAEs requiring hospitalization: three on AIs (con- congruent with recently published positive results using
The Endocrine Society. Downloaded from press.endocrine.org by [Elham Faghihimani] on 26 December 2016. at 04:12 For personal use only. No other uses without permission. . All rights reserved.
doi: 10.1210/jc.2016-2891
AI/GH vs GH alone for 11–19 months in a small cohort
(n ⫽ 24) of 15-year-old boys with ISS treated at the end of
puberty (26).
Whenever possible, we followed these young men to
near-adult height for 1–2 years after discontinuation of all
study drugs, with a mean age of 17.4 years and bone age
of 15.3 years when approximately 97.6% of adult height
had been achieved (23). In aggregate, regardless of the
length of treatment, absolute height changes from baseline
to near-final height were: AI, ⫹18.2 (1.6) cm; GH, ⫹20.6
(1.5) cm; and AI/GH, ⫹22.5 (1.4) cm (P ⫽ .01 between
groups). Height gains were greater if treatments were continued through 36 months compared to baseline: AI,
⫹23.8 (2.3) cm; GH, ⫹26.7 (2.0) cm; and AI/GH, ⫹30.7
(1.1) cm. These gains in height also compare favorably
with the expected height gain from 14.1 to 17.4 years of
⫹13.0 cm for boys with a height SDS of ⫺2.0 (our subjects, ⫺2.2 to ⫺2.4).
Calculated differences between estimated target (midparental) height and near-final height showed modest
group differences of ⫺7.8, ⫺5.3, and ⫺4.5 cm shorter
than the target for AI, GH, and AI/GH, respectively. This
likely overestimates the differences between near-final and
target height because often we could not measure the
height of both parents, and adults often tend to overestimate their own height. However, these results underscore
the positive impact of these growth-promoting therapies,
even when initiated in the midst of puberty. Multiple subjects ended up taller than the target height.
We carefully assessed bone health during these interventions. Bone density of the lumbar spine—which reflects
trabecular bone—was normal once corrected for the subjects’ height (24) compared to age appropriate normative
data. It remained within the normal range with all interventions for 24 months, although with AI alone it was less
(corrected Z-score, ⫺1.06). BMD Z-scores corrected for
height were mildly low in all groups at the whole-body
level—which reflects mostly cortical bone—and remained
constant with interventions after 24 months of treatment.
This is comparable to the lack of change in BMD in our
previous reports in GH-deficient boys treated with GH
and anastrozole (19) and in ISS boys treated with letrozole
(18). Bone-specific alkaline phosphatase, a marker of bone
formation, was the same regardless of treatment arm.
AIs were previously reported to be associated with vertebral irregularities in a group of boys with ISS or constitutional growth delay treated with letrozole (17, 18, 27).
We therefore carefully assessed vertebral changes focusing
on the thoracic spine. We found no differences in the three
groups for disc space narrowing, wedging, compression,
and overall vertebral irregularities during the 24-month
treatment. Actually, some of these findings were present at
press.endocrine.org/journal/jcem
4991
baseline, and some were no longer detected (such as compression) as treatment progressed. The extent of these abnormalities was indeed very mild and was similar to those
commonly seen in short adolescents (28, 29). Bone pain
questionnaires did not reveal any differences between
groups (data not shown). Overall, the use of AIs, either
alone or in combination, was not detrimental to bone
health when used for up to 3 years.
A secondary outcome of these studies was to assess
differential effects of AIs on body composition compared to GH (alone or in combination) in adolescents
with ISS. Youngsters with short stature not due to GH
deficiency are often skinny and have poor muscle mass
(30). AIs and GH, when given alone, had a comparable
positive impact on FFM accrual (AI, ⫹11.5 [1.1] kg;
GH, ⫹12.1 [1.1] kg), but combination treatment had a
clearly greater effect on FFM (⫹15.4 [1.4] kg) after 24
months. This is likely secondary to the potent proteinanabolic effects of the increase in androgens (14, 31)
plus GH (32). The GH-alone and AI/GH groups had
lower percentages of fat mass than the AI-alone group.
In aggregate, combination AI/GH had a positive effect
on body composition, increasing FFM and decreasing
adiposity in these adolescents.
Plasma IGF-1 concentrations remained comparable
throughout the first 24 months of the study in the AI-alone
group, whereas they increased in the GH and AI/GH
groups. This is congruent with the well-established effect
of estrogen enhancing GH, and hence IGF-1 production
(33, 34). The increase in growth in the AI-only group,
despite a lack of increase in IGF-1, is similar to previously
reported effects using letrozole in ISS boys (18) and to the
increased growth observed with oxandrolone, a nonaromatizable androgen (34 –36). Although mechanisms of
growth increase without an IGF-1 increase are not fully
characterized, this suggests a direct effect of androgens on
the epiphyseal growth plate, likely mediated via the androgen receptor (37–39).
As expected, aromatase blockade caused a significant
increase in circulating T concentrations and a reciprocal
decline in estradiol whether administered alone or in combination with GH. We examined the relative impact of
aromatase blockade on sex steroids depending on AI used,
and letrozole caused greater T and lesser estradiol concentrations than anastrozole. In postmenopausal women,
an 88% vs 85% tissue aromatase blockade has been reported for letrozole vs anastrozole (P ⫽ not significant)
(40), with mean residual estradiol concentrations of
10.1% for anastrozole and 5.9% for letrozole (41), findings also confirmed by others (40) and congruent with our
findings. There is, however, no difference in breast cancer
survival using anastrozole vs letrozole (40, 41). Our study
The Endocrine Society. Downloaded from press.endocrine.org by [Elham Faghihimani] on 26 December 2016. at 04:12 For personal use only. No other uses without permission. . All rights reserved.
4992
Mauras et al
Aromatase Inhibitors (AI), GH & AI/GH in ISS Boys
was not powered to detect differences in any of the principal clinical outcomes such as growth or body composition by AI, but letrozole will likely increase T more than
anastrozole, necessitating closer monitoring of sex steroid
levels. Any differential effects on growth would await further study.
The use of AIs, alone or with GH, was well tolerated
and was safe overall. The incidence of AEs was comparable, and SAEs were not likely related to study drugs, except
for one occurrence of SCFE. All chemistries, including
liver function and plasma lipids, remained within normal
limits throughout the study.
In summary, the use of combination AI/GH improved
linear growth ⬎ GH alone and AIs alone in adolescent
boys with ISS naive to treatment who were started on
treatment in adolescence and treated for 24 months. Linear growth was improved further with more prolonged
(36 months total) treatment in those with residual growth
potential. Regardless of the length of treatment, near-final
height gains were: AI, ⫹18.2 (1.6) cm; GH, ⫹20.6 (1.5)
cm; and AI/GH, ⫹22.5 (1.4) cm; resulting in the following
near-adult height SDS: AI, ⫺1.4 (0.1) cm; GH, ⫺1.4 (0.2)
cm; and AI/GH, ⫺1.0 (0.1) cm. FFM accrual was greater
in the AI/GH group. Measures of bone health showed no
detrimental effects with AIs. Anastrozole and letrozole
had differential effects on sex steroid concentrations, with
greater T and lesser estradiol in those treated with letrozole vs anastrozole. AIs alone and in combination with GH
were well tolerated and safe for up to 3 years. In conclusion, AIs are an alternative treatment to enhance linear
growth in adolescent boys with ISS, particularly in combination with GH.
Acknowledgments
The authors are grateful for the technical support of Shawn
Sweeten in the Biochemical Analysis Laboratory at the Nemours
Children’s Health System in Jacksonville, Florida, as well as the
technical support at Dr. Ravinder Singh’s laboratory at the Mayo
Clinic, Rochester, Minnesota. We are grateful to Karen Kowal,
physician assistant at the Nemours Clinic at Jefferson University
and Dupont Hospital for Children, for her excellent care of these
patients; to Sylvia Kyle, Nemours librarian, for her outstanding
assistance; to Genentech, Pfizer, Novartis, and AstraZeneca for
providing drug supplies for these studies; and for a generous
grant from Mr. W. J. Wadsworth and the Thrasher Research
Fund, who funded these studies. Our thanks go to the data safety
management board, including Edward Reiter, MD; Janet Silverstein, MD; and Pamela Arn, MD. We are also grateful to the
physicians who referred patients and all the adolescent boys and
their parents who participated in these studies.
J Clin Endocrinol Metab, December 2016, 101(12):4984 – 4993
Address all correspondence and requests for reprints to: Nelly
Mauras, MD, Nemours Children’s Health System, 807 Children’s
Way, Jacksonville, FL 32207. E-mail: nmauras@nemours.org.
This work was supported by grants from the Thrasher Research Fund (to N.M.), National Institutes of Health Grant UL1
TR000135 from the National Center for Advancing Translational Sciences (to R.S.), a generous gift from W. J. Wadsworth
(to N.M.), and drug supply agreements from AstraZeneca, Novartis, Genentech, and Pfizer.
Clinical Trial Registration No.: NCT01248416.
Disclosure Summary: N.M. has received research support in
drug supply agreements from Genentech, Pfizer, Novartis and
AstraZeneca; and consulted for Opko. J.R. receives research support from Versartis and Novo Nordisk and consults for Novo
Nordisk. All other authors have nothing to declare.
References
1. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J. High dose
recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized,
multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin
Endocrinol Metab. 2000;85(10):3653–3660.
2. Mericq MV, Eggers M, Avila A, Cutler GB Jr, Cassorla F. Near final
height in pubertal growth hormone (GH)-deficient patients treated
with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial. J Clin
Endocrinol Metab. 2000;85(2):569 –573.
3. Pucarelli I, Segni M, Ortore M, Arcadi E, Pasquino AM. Effects of
combined gonadotropin-releasing hormone agonist and growth
hormone therapy on adult height in precocious puberty: a further
contribution. J Pediatr Endocrinol Metab. 2003;16(7):1005–1010.
4. Reiter EO. A brief review of the addition of gonadotropin-releasing
hormone agonists (GnRH-Ag) to growth hormone (GH) treatment
of children with idiopathic growth hormone deficiency: previously
published studies from America. Mol Cell Endocrinol. 2006;254 –
255:221–225.
5. Scalco RC, Melo SS, Pugliese-Pires PN, et al. Effectiveness of the
combined recombinant human growth hormone and gonadotropinreleasing hormone analog therapy in pubertal patients with short
stature due to SHOX deficiency. J Clin Endocrinol Metab. 2010;
95(1):328 –332.
6. Lem AJ, van der Kaay DC, de Ridder MA, et al. Adult height in short
children born SGA treated with growth hormone and gonadotropin
releasing hormone analog: results of a randomized, dose-response
GH trial. J Clin Endocrinol Metab. 2012;97(11):4096 – 4105.
7. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a
mutation in the estrogen-receptor gene in a man. N Engl J Med.
1994;331(16):1056 –1061.
8. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol
in a man with aromatase deficiency. N Engl J Med. 1997;337(2):
91–95.
9. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel
mutation and the physiological role of estrogens. J Clin Endocrinol
Metab. 1995;80(12):3689 –3698.
10. Gunther DF, Calikoglu AS, Underwood LE. The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice. Pediatr Res. 1999;46(3):269 –273.
11. Nilsson O, Weise M, Landman EB, Meyers JL, Barnes KM, Baron
J. Evidence that estrogen hastens epiphyseal fusion and cessation of
longitudinal bone growth by irreversibly depleting the number of
resting zone progenitor cells in female rabbits. Endocrinology.
2014;155(8):2892–2899.
The Endocrine Society. Downloaded from press.endocrine.org by [Elham Faghihimani] on 26 December 2016. at 04:12 For personal use only. No other uses without permission. . All rights reserved.
doi: 10.1210/jc.2016-2891
12. Mauras N, Lima J, Patel D, et al. Pharmacokinetics and dose finding
of a potent aromatase inhibitor, aromasin (exemestane), in young
males. J Clin Endocrinol Metab. 2003;88(12):5951–5956.
13. Mauras N, Bishop K, Merinbaum D, Emeribe U, Agbo F, Lowe E.
Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. J Clin Endocrinol Metab.
2009;94(8):2975–2978.
14. Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young
men: marked alterations in whole body protein kinetics, strength,
and adiposity. J Clin Endocrinol Metab. 1998;83(6):1886 –1892.
15. Mauras N, Hayes VY, Vieira NE, Yergey AL, O’Brien KO. Profound hypogonadism has significant negative effects on calcium balance in males: a calcium kinetic study. J Bone Miner Res. 1999;
14(4):577–582.
16. Mauras N, O’Brien KO, Klein KO, Hayes V. Estrogen suppression
in males: metabolic effects. J Clin Endocrinol Metab. 2000;85(7):
2370 –2377.
17. Wickman S, Sipil I, Ankarberg-Lindgren C, Norjavaara E, Dunkel
L. A specific aromatase inhibitor and potential increase in adult
height in boys with delayed puberty: a randomised controlled trial.
Lancet. 2001;357(9270):1743–1748.
18. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult
height in boys with idiopathic short stature: a randomized controlled
trial. J Clin Endocrinol Metab. 2005;90(12):6396 – 6402.
19. Mauras N, Gonzalez de Pijem L, Hsiang HY, et al. Anastrozole
increases predicted adult height of short adolescent males treated
with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab. 2008;
93(3):823– 831.
20. Tanner J. Growth at Adolescence. 2nd ed. Oxford, UK: Blackwell
Scientific Publications; 1962.
21. Ettinger B, Black DM, Nevitt MC, et al. Contribution of vertebral
deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1992;7(4):
449 – 456.
22. Roche AF, Chumlea WC, Thissen D. Assessing the Skeletal Maturity
of the Hand-Wrist: Fels Method. Springfield, IL: Charles C. Thomas;
1988.
23. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952;40(4):423– 441.
24. Zemel BS, Kalkwarf HJ, Gilsanz V, et al. Revised reference curves
for bone mineral content and areal bone mineral density according
to age and sex for black and non-black children: results of the Bone
Mineral Density in Childhood Study. J Clin Endocrinol Metab.
2011;96(10):3160 –3169.
25. Centers for Disease Control and Prevention. National Center for
Growth Statistics. CDC Growth charts. Z-score data tables. http://
www.cdc.gov/growthcharts/zscore.htm. Accessed July 12, 2016.
26. Rothenbuhler A, Linglart A, Bougnres P. A randomized pilot trial of
growth hormone with anastrozole versus growth hormone alone,
starting at the very end of puberty in adolescents with idiopathic
short stature. Int J Pediatr Endocrinol. 2015(1);2015:4.
27. Hero M, Toiviainen-Salo S, Wickman S, Mitie O, Dunkel L. Vertebral morphology in aromatase inhibitor-treated males with idio-
press.endocrine.org/journal/jcem
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
4993
pathic short stature or constitutional delay of puberty. J Bone Miner
Res. 2010;25(7):1536 –1543.
Ramadorai U, Hire J, DeVine JG, Brodt ED, Dettori JR. Incidental
findings on magnetic resonance imaging of the spine in the asymptomatic pediatric population: a systematic review. Evid Based Spine
Care J. 2014;5(2):95–100.
Jaremko JL, Siminoski K, Firth GB, et al. Common normal variants
of pediatric vertebral development that mimic fractures: a pictorial
review from a national longitudinal bone health study. Pediatr Radiol. 2015;45(4):593– 605.
Han JC, Balagopal P, Sweeten S, Darmaun D, Mauras N. Evidence
for hypermetabolism in boys with constitutional delay of growth
and maturation. J Clin Endocrinol Metab. 2006;91(6):2081–2086.
Mauras N, Haymond MW, Darmaun D, Vieira NE, Abrams SA,
Yergey AL. Calcium and protein kinetics in prepubertal boys. Positive effects of testosterone. J Clin Invest. 1994;93(3):1014 –1019.
Mauras N, Haymond MW. Are the metabolic effects of GH and
IGF-I separable? Growth Horm IGF Res. 2005;15(1):19 –27.
Veldhuis JD, Roemmich JN, Richmond EJ, et al. Endocrine control
of body composition in infancy, childhood, and puberty. Endocr
Rev. 2005;26(1):114 –146.
Veldhuis JD, Metzger DL, Martha PM Jr, et al. Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal
pathophysiology and sex-steroid hormone replacement. J Clin Endocrinol Metab. 1997;82(10):3414 –3420.
Sas TC, Gault EJ, Bardsley MZ, et al. Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome:
evidence from recent studies and recommendations for use. Horm
Res Paediatr. 2014;81(5):289 –297.
Vottero A, Pedori S, Verna M, et al. Final height in girls with central
idiopathic precocious puberty treated with gonadotropin-releasing
hormone analog and oxandrolone. J Clin Endocrinol Metab. 2006;
91(4):1284 –1287.
Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of androgen receptors in human bone. J Clin Endocrinol
Metab. 1997;82(10):3493–3497.
van der Eerden BC, van Til NP, Brinkmann AO, Lowik CW, Wit
JM, Karperien M. Gender differences in expression of androgen
receptor in tibial growth plate and metaphyseal bone of the rat.
Bone. 2002;30(6):891– 896.
Nilsson O, Chrysis D, Pajulo O, et al. Localization of estrogen receptors-alpha and -beta and androgen receptor in the human growth
plate at different pubertal stages. J Endocrinol. 2003;177(2):319 –
326.
Sendur MA, Aksoy S, Zengin N, Altundag K. Comparative efficacy
study of 5-year letrozole or anastrozole in postmenopausal hormone
receptor-positive early breast cancer. J BUON. 2013;18(4):838 –
844.
Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant
comparison between letrozole, anastrozole, and exemestane for
postmenopausal women with estrogen receptor-rich stage 2 to 3
breast cancer: clinical and biomarker outcomes and predictive value
of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031.
J Clin Oncol. 2011;29(17):2342–2349.
The Endocrine Society. Downloaded from press.endocrine.org by [Elham Faghihimani] on 26 December 2016. at 04:12 For personal use only. No other uses without permission. . All rights reserved.